<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene G142D;E154K;L452R;E484Q;D614G;P681R;Q1071H literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.G142D;E154K;L452R;E484Q;D614G;P681R;Q1071H</span> literature reference collection</h1>
<div class="effect_section"><h2 id="ACE2_receptor_binding_affinity">ACE2 receptor binding affinity</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination (representing lineage B.1.617.1) showed a 1.12x increase  in binding (KD) relative to D614G, but described as "not significant". [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing lineage B.1.617.1) showed a 2x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 8 months post-symptom-onset. [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="convalescent_plasma_escape">Convalescent plasma escape</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Relative to B.1, Kappa (B.1.617.1) shows 5.71x decrease in neutralization efficiency by convalescent plasma [no cohort details provided] (<a href="https://doi.org/10.1101/2021.08.09.21261704" class="lit_link">Wilhelm et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="trafficking">Trafficking</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> ~3.5x cleavage of S2 relative to WA1 (D614G) wildtype by Kappa (B.1.617.1) variant as measured by mass spectrometry of Vero-TMPRSS culture (compare to ~4.5x for closely related Delta B.1.617.2 also with P681R at the cleavage site). <br/> (<a href="https://doi.org/10.1101/2021.08.05.455290" class="lit_link">Esclera et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Relative to B.1, Kappa (B.1.617.1) shows mean 1.97x decrease in neutralization efficiency by 18 vaccinee sera (BNT162b2 and mRNA1273).<br/> (<a href="https://doi.org/10.1101/2021.08.09.21261704" class="lit_link">Wilhelm et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Inferring from two B.1.617.1 variants tested, estimate baseline 3.3x reduction in ID50 relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.<br/> (<a href="https://doi.org/10.1101/2021.06.28.449914" class="lit_link">Choi et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> 1.5x reduction in neutralization (ID50) in sera 3 weeks after one dose of Pfizer/BioNTech BNT162b2 (up to 5 naive and post infection vaccinees) [exact set of variants used is not listed in the manuscript] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Average 2x neutralization efficiency decrease against sera from 26 Phase II trial Covaxin (BBV152) vaccine recipents.<br/>Very similar to B.1.1.7 (~2x) in the same study, and the neutralization from 17 sera of natural infections across B1 lineages. (<a href="https://doi.org/10.1101/2021.04.23.441101" class="lit_link">Yadav et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> This variant combination (representing lineage B.1.617.1) showed a 1.79x decrease in Spike binding (relative to D614G alone)  by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects. <br/> 1.64x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.<br/> [exact variant list not provided in manuscript, is inferred and  represents minimal set agreed upon commonly] (<a href="https://doi.org/10.1101/2021.08.04.455140" class="lit_link">Gong et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
